FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to new immunoglobulin conjugates with different agents. The invention discloses a method for producing immunoglobulins conjugated through the chemistry of amino acid residues of cysteine in special positions of a variable region of an immunoglobulin light chain (“Cys80”). The invention also relates to conjugates of hybrid or humanized rabbit immunoglobulins that immune-specifically bind to CA9, TEM1 or human mesothelin, as well as discloses the possibility of using such conjugates in the therapy of cancer diseases.
EFFECT: obtaining Cys80-conjugated immunoglobulins for use in the cancer therapy.
32 cl, 23 dwg, 6 ex, 27 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
